Report
Our reports provide latest industry trends, forecasts, company profiles, competitive landscape, and strategic insights.
Europe Benign Prostatic Hyperplasic Devices Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Product (Resectoscopes, Urology Laser, Radiofrequency Ablation Devices, Prostatic Stents, and Implants), Procedure Type (Transurethral Microwave Therapy, Transurethral Resection of the Prostate, Transurethral Needle Ablation of the Prostate, Laser Surgery, Urolift Surgery, and Others), and End User (Hospitals, Clinics, Ambulatory Surgical Centers, and Others)
- Report Code : BMIRE00027126
- Pages : 159
The benign prostatic hyperplasic devices market in Europe is expected to grow from US$ 648.39 million in 2022 to US$ 994.84 million by 2028; it is estimated to grow at a CAGR of 7.4% from 2022 to 2028.
Players operating in the benign prostatic hyperplasic devices industry focus on investing high amounts in the development of advanced surgical technologies as alternatives to conventional techniques. Advanced devices enabled with new technologies help provide immediate relief and reduce morbidity. In January 2022, ProVerum, an Irish start-up supported by EIT Health, received US$ 31.22 million in Series A funding from Gilde Healthcare, Lightstone Ventures, and Atlantic Bridge. ProVerum has developed ProVee, a cutting-edge treatment solution for men with symptomatic BPH, and it aims to market its innovative device in Europe with the help of recent funding. Further, in June 2021, Zenflow, Inc., a medical device company developing a minimally invasive treatment for urinary obstruction caused by BPH or enlarged prostate, declared the completion of its Series B funding round with a total of US$ 24 million. The investment was led by Invus Opportunities and included participation from Medical Technology Venture Partners, F-Prime Capital, CloudStone Capital, Astia Angels, Golden Seeds, SV Tech Ventures, etc. In June 2021, Procept Biorobotics raised US$ 85 million to commercialize the AquaBeam system as a global BPH treatment. With this product, the company intends to make an impact with its water-based robotic technology in the field of prostate surgery. The series G financing was led by Fidelity Management & Research Company, with additional backing from T. Rowe Price Associates, CPMG, Perceptive Advisors, Viking Global Investors, and Duquesne Family Office. The rise in such investments, funds, and grants for research in the field of BPH treatments is bolstering the benign prostatic hyperplasic devices market growth.
Europe Benign Prostatic Hyperplasic Devices Market Revenue and Forecast to 2028 (US$ Million)
Europe Benign Prostatic Hyperplasic Devices Market Segmentation
The Europe benign prostatic hyperplasic devices market is segmented on the basis of product, procedure type, end user, and country. Based on product, the market is segmented into resectoscopes, urology lasers, radiofrequency ablation devices, prostatic stents, and implants. The resectoscopes segment is expected to hold the largest share of the market in 2022. On the other hand, the urology lasers segment is expected to register the highest CAGR during the forecast period. Based on procedure type, the Europe benign prostatic hyperplasic devices market is segmented into transurethral microwave therapy, transurethral resection of the prostate, transurethral needle ablation of the prostate, laser surgery, urolift surgery, and others. The transurethral resection of the prostate segment held the largest market share in 2022, and it is also expected to register the highest CAGR in the market during the forecast period. Based on end user, the Europe benign prostatic hyperplasic devices market is segmented into hospitals, clinics, ambulatory surgical centers, and others. The hospital segment held the largest market share in 2022, while the clinics segment is expected to register the highest CAGR during the forecast period. Based on country, the Europe benign prostatic hyperplasic devices market is segmented into U.K., Germany, France, Italy, Spain, and Rest of Europe. In 2022, Germany held a larger market share. On the other side, and it is also expected to register a higher CAGR during the forecast period.
KARL STORZ SE & Co. KG; Olympus Corporation; Boston Scientific Corporation; Teleflex Incorporated; and Richard Wolf GmbH are among the leading companies in the Europe benign prostatic hyperplasic devices market.
TABLE OF CONTENTS
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Europe Benign Prostatic Hyperplasic Devices Market – By Product
1.3.2 Europe Benign Prostatic Hyperplasic Devices Market – By Procedure Type
1.3.3 Europe Benign Prostatic Hyperplasic Devices Market – By End User
1.3.4 Europe Benign Prostatic Hyperplasic Devices Market – By Country
2. Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Europe Benign Prostatic Hyperplasic Devices Market Landscape
4.1 Overview
4.2 PEST Analysis
4.3 Experts Opinion
5. Europe Benign Prostatic Hyperplasic Devices Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Burgeoning Prevalence of Benign Prostatic Hyperplasia along with Growing Risk Factors
5.1.2 Growing Investments, Funds, and Grants for Research in BPH Treatment
5.1 Market Restraints
5.1.1 Restricted Awareness of Prostate Health Among Men
5.2 Market Opportunities
5.2.1 Emerging Markets
5.3 Future Trends
5.3.1 Widening Product Approvals and Launches
5.4 Impact Analysis
6. Europe Benign Prostatic Hyperplasic Devices Market Analysis
6.1 Europe Benign Prostatic Hyperplasic Devices Market Revenue Forecast and Analysis
7. Asia Pacific Benign Prostatic Hyperplasic Devices Market – by Product
7.1 Asia Pacific Benign Prostatic Hyperplasic Devices Market Revenue Share, by Product (2022 and 2028)
7.2 Resectoscopes
7.2.1 Overview
7.2.2 Resectoscopes: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
7.3 Urology Lasers
7.3.1 Overview
7.3.2 Urology Lasers: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
7.4 Radiofrequency Ablation Devices
7.4.1 Overview
7.4.2 Radiofrequency Ablation Devices: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
7.5 Prostatic Stents
7.5.1 Overview
7.5.2 Prostatic Stents: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
7.6 Implants
7.6.1 Overview
7.6.2 Implants: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
8. Europe Benign Prostatic Hyperplasic Devices Market – by Procedure Type
8.1 Europe Benign Prostatic Hyperplasic Devices Market Revenue Share, by Procedure Type (2022 and 2028)
8.2 Transurethral Microwave Therapy
8.2.1 Overview
8.2.2 Transurethral Microwave Therapy: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
8.3 Transurethral Resection of the Prostate
8.3.1 Overview
8.3.2 Transurethral Resection of the Prostate: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
8.4 Transurethral Needle Ablation of the Prostate
8.4.1 Overview
8.4.2 Transurethral Needle Ablation of the Prostate: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
8.5 Laser Surgery
8.5.1 Overview
8.5.2 Laser Surgery: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
8.6 UroLift Surgery
8.6.1 Overview
8.6.2 UroLift Surgery: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
8.7 Others
8.7.1 Overview
8.7.2 Others: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
9. Europe Benign Prostatic Hyperplasic Devices Market – by End User
9.1 Overview
9.2 Europe Benign Prostatic Hyperplasic Devices Market Revenue Share, by End User (2022 and 2028)
9.3 Hospitals
9.3.1 Overview
9.3.2 Hospitals Market Revenue and Forecast to 2028 (US$ Million)
9.4 Clinics
9.4.1 Overview
9.4.2 Clinics Market Revenue and Forecast to 2028 (US$ Million)
9.5 Ambulatory Surgical Centers
9.5.1 Overview
9.5.2 Ambulatory Surgical Centers Market Revenue and Forecast to 2028 (US$ Million)
9.6 Others
9.6.1 Overview
9.6.2 Others Market Revenue and Forecast to 2028 (US$ Million)
10. Europe Benign Prostatic Hyperplasic Devices Market – by Country Analysis
10.1 Overview
10.1.1 Europe: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
10.1.2 Europe: Benign Prostatic Hyperplasic Devices Market, by Product– Revenue and Forecast to 2028 (US$ Million)
10.1.3 Europe: Benign Prostatic Hyperplasic Devices Market, by Procedure Type – Revenue and Forecast to 2028 (US$ Million)
10.1.4 Europe: Benign Prostatic Hyperplasic Devices Market, by End User – Revenue and Forecast to 2028 (US$ Million)
10.1.5 Europe: Benign Prostatic Hyperplasic Devices Market, by Country, 2022 & 2028 (%)
10.1.5.1 UK: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
10.1.5.1.1 Overview
10.1.5.1.2 UK: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
10.1.5.1.3 UK: Benign Prostatic Hyperplasic Devices Market, by Product– Revenue and Forecast to 2028 (US$ Million)
10.1.5.1.4 UK: Benign Prostatic Hyperplasic Devices Market, by Procedure Type – Revenue and Forecast to 2028 (US$ Million)
10.1.5.1.5 UK: Benign Prostatic Hyperplasic Devices Market, by End User – Revenue and Forecast to 2028 (US$ Million)
10.1.5.2 Germany: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
10.1.5.2.1 Overview
10.1.5.2.2 Germany: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
10.1.5.2.3 Germany: Benign Prostatic Hyperplasic Devices Market, by Product– Revenue and Forecast to 2028 (US$ Million)
10.1.5.2.4 Germany: Benign Prostatic Hyperplasic Devices Market, by Procedure Type – Revenue and Forecast to 2028 (US$ Million)
10.1.5.2.5 Germany: Benign Prostatic Hyperplasic Devices Market, by End User – Revenue and Forecast to 2028 (US$ Million)
10.1.5.3 France: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
10.1.5.3.1 Overview
10.1.5.3.2 France: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
10.1.5.3.3 France: Benign Prostatic Hyperplasic Devices Market, by Product– Revenue and Forecast to 2028 (US$ Million)
10.1.5.3.4 France: Benign Prostatic Hyperplasic Devices Market, by Procedure Type – Revenue and Forecast to 2028 (US$ Million)
10.1.5.3.5 France: Benign Prostatic Hyperplasic Devices Market, by End User – Revenue and Forecast to 2028 (US$ Million)
10.1.5.4 Italy: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
10.1.5.4.1 Overview
10.1.5.4.2 Italy: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
10.1.5.4.3 Italy: Benign Prostatic Hyperplasic Devices Market, by Product– Revenue and Forecast to 2028 (US$ Million)
10.1.5.4.4 Italy: Benign Prostatic Hyperplasic Devices Market, by Procedure Type – Revenue and Forecast to 2028 (US$ Million)
10.1.5.4.5 Italy: Benign Prostatic Hyperplasic Devices Market, by End User – Revenue and Forecast to 2028 (US$ Million)
10.1.5.5 Spain: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
10.1.5.5.1 Overview
10.1.5.5.2 Spain: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
10.1.5.5.3 Spain: Benign Prostatic Hyperplasic Devices Market, by Product– Revenue and Forecast to 2028 (US$ Million)
10.1.5.5.4 Spain: Benign Prostatic Hyperplasic Devices Market, by Procedure Type – Revenue and Forecast to 2028 (US$ Million)
10.1.5.5.5 Spain: Benign Prostatic Hyperplasic Devices Market, by End User – Revenue and Forecast to 2028 (US$ Million)
10.1.5.6 Rest of Europe: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
10.1.5.6.1 Overview
10.1.5.6.2 Rest of Europe: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
10.1.5.6.3 Rest of Europe: Benign Prostatic Hyperplasic Devices Market, by Product– Revenue and Forecast to 2028 (US$ Million)
10.1.5.6.4 Rest of Europe: Benign Prostatic Hyperplasic Devices Market, by Procedure Type – Revenue and Forecast to 2028 (US$ Million)
10.1.5.6.5 Rest of Europe: Benign Prostatic Hyperplasic Devices Market, by End User – Revenue and Forecast to 2028 (US$ Million)
11. Europe Benign Prostatic Hyperplasic Devices Market – Industry Landscape
11.1 Overview
11.2 Inorganic Growth Strategies
11.3 Organic Growth Strategies
12. Company Profiles
12.1 KARL STORZ SE & Co. KG
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Richard Wolf GmbH
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Olympus Corporation
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Boston Scientific Corporation
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Teleflex Incorporated
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
13. Appendix
13.1 About The Insight Partners
13.2 Glossary of Terms for Europe Benign Prostatic Hyperplasia Devices Market
LIST OF TABLES
Table 1. Europe: Benign Prostatic Hyperplasic Devices Market, by Product– Revenue and Forecast to 2028 (US$ Million)
Table 2. Europe: Benign Prostatic Hyperplasic Devices Market, by Procedure Type – Revenue and Forecast to 2028 (US$ Million)
Table 3. Europe: Benign Prostatic Hyperplasic Devices Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 4. UK: Benign Prostatic Hyperplasic Devices Market, by Product– Revenue and Forecast to 2028 (US$ Million)
Table 5. UK: Benign Prostatic Hyperplasic Devices Market, by Procedure Type – Revenue and Forecast to 2028 (US$ Million)
Table 6. UK: Benign Prostatic Hyperplasic Devices Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 7. Germany: Benign Prostatic Hyperplasic Devices Market, by Product– Revenue and Forecast to 2028 (US$ Million)
Table 8. Germany: Benign Prostatic Hyperplasic Devices Market, by Procedure Type – Revenue and Forecast to 2028 (US$ Million)
Table 9. Germany: Benign Prostatic Hyperplasic Devices Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 10. France: Benign Prostatic Hyperplasic Devices Market, by Product– Revenue and Forecast to 2028 (US$ Million)
Table 11. France: Benign Prostatic Hyperplasic Devices Market, by Procedure Type – Revenue and Forecast to 2028 (US$ Million)
Table 12. France: Benign Prostatic Hyperplasic Devices Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 13. Italy: Benign Prostatic Hyperplasic Devices Market, by Product– Revenue and Forecast to 2028 (US$ Million)
Table 14. Italy: Benign Prostatic Hyperplasic Devices Market, by Procedure Type – Revenue and Forecast to 2028 (US$ Million)
Table 15. Italy: Benign Prostatic Hyperplasic Devices Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 16. Spain: Benign Prostatic Hyperplasic Devices Market, by Product– Revenue and Forecast to 2028 (US$ Million)
Table 17. Spain: Benign Prostatic Hyperplasic Devices Market, by Procedure Type – Revenue and Forecast to 2028 (US$ Million)
Table 18. Spain: Benign Prostatic Hyperplasic Devices Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 19. Rest of Europe: Benign Prostatic Hyperplasic Devices Market, by Product– Revenue and Forecast to 2028 (US$ Million)
Table 20. Rest of Europe: Benign Prostatic Hyperplasic Devices Market, by Procedure Type – Revenue and Forecast to 2028 (US$ Million)
Table 21. Rest of Europe: Benign Prostatic Hyperplasic Devices Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 22. Recent Inorganic Growth Strategies in the Benign Prostatic Hyperplasia Devices Market
Table 23. Recent Organic Growth Strategies in the Benign Prostatic Hyperplasia Devices Market
Table 24. Glossary of Terms
LIST OF FIGURES
Figure 1. Europe Benign Prostatic Hyperplasic Devices Market Segmentation
Figure 2. Europe Benign Prostatic Hyperplasic Devices Market, By Country
Figure 3. Europe Benign Prostatic Hyperplasic Devices Market Overview
Figure 4. Resectoscopes Segment Held Largest Share of Product Segment in Benign Prostatic Hyperplasic Devices Market
Figure 5. Germany is Expected to Show Remarkable Growth During the Forecast Period
Figure 6. Europe Benign Prostatic Hyperplasic Devices Market, Industry Landscape
Figure 7. Europe: PEST Analysis
Figure 8. Experts Opinion
Figure 9. Europe Benign Prostatic Hyperplasic Devices Market – Revenue Forecast and Analysis – 2020-2028
Figure 10. Asia Pacific Benign Prostatic Hyperplasic Devices Market Revenue Share, by Product (2022 and 2028)
Figure 11. Resectoscopes: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
Figure 12. Urology Lasers: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
Figure 13. Radiofrequency Ablation Devices: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
Figure 14. Prostatic Stents: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
Figure 15. Implants: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
Figure 16. Europe Benign Prostatic Hyperplasic Devices Market Revenue Share, by Procedure Type (2022 and 2028)
Figure 17. Transurethral Microwave Therapy: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
Figure 18. Transurethral Resection of the Prostate: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
Figure 19. Transurethral Needle Ablation of the Prostate: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
Figure 20. Laser Surgery: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
Figure 21. UroLift Surgery: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
Figure 22. Others: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
Figure 23. Europe Benign Prostatic Hyperplasic Devices Market Revenue Share, by End User (2022 and 2028)
Figure 24. Hospitals Market Revenue and Forecast to 2028 (US$ Million)
Figure 25. Clinics Market Revenue and Forecast to 2028 (US$ Million)
Figure 26. Ambulatory Surgical Centers Market Revenue and Forecast to 2028 (US$ Million)
Figure 27. Others Market Revenue and Forecast to 2028 (US$ Million)
Figure 28. Europe: Benign Prostatic Hyperplasic Devices Market, by Key Country – Revenue (2022) (US$ Million)
Figure 29. Europe: Benign Prostatic Hyperplasic Devices Market Revenue and Forecast to 2028 (US$ Million)
Figure 30. Europe: Benign Prostatic Hyperplasic Devices Market, by Country, 2022 & 2028 (%)
Figure 31. UK: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
Figure 32. Germany: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
Figure 33. France: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
Figure 34. Italy: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
Figure 35. Spain: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
Figure 36. Rest of Europe: Benign Prostatic Hyperplasic Devices Market – Revenue and Forecast to 2028 (US$ Million)
● Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Europe benign prostatic hyperplasic devices market.
● Highlights key business priorities in order to assist companies to realign their business strategies
● The key findings and recommendations highlight crucial progressive industry trends in the Europe benign prostatic hyperplasic devices market, thereby allowing players across the value chain to develop effective long-term strategies
● Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
● Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the benign prostatic hyperplasic devices market, as well as those hindering it
● Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution
The List of Companies – Europe Benign Prostatic Hyperplasic Devices Market
● KARL STORZ SE & Co. KG
● Olympus Corporation
● Boston Scientific Corporation
● Teleflex Incorporated
● Richard Wolf GmbH
● GmbH
At 7.4% CAGR, the Europe Benign Prostatic Hyperplasic Devices Market is speculated to be worth US$ 994.84 million by 2028, says The Insight Partners
According to The Insight Partners’ research, the Europe benign prostatic hyperplasic devices market was valued at US$ 648.39 million in 2022 and is expected to reach US$ 994.84 million by 2028, registering an annual growth rate of 7.4% from 2022 to 2028. Widening product approvals and launches and growing investments, funds, and grants for research in BPH treatment.
The benign prostatic hyperplasic devices market includes many small and big companies. Market players are adopting various strategies to increase their market shares; these include new product launches, regional expansion, and technological advancements. With continued innovation, benign prostatic hyperplasic devices are becoming safer, and treatments are becoming easier and more effective than ever. This is driving the acceptance of benign prostatic hyperplasic devices across the region. A few of the recent developments in the benign prostatic hyperplasic devices market are: In April 2020, Olympus announced the approval of iTind, its nonsurgical medical device, for the minimally invasive surgery of BPH. This is a temporarily urethral opening device that has been given a De Novo classification by the FDA and is a Class II medical device. The active participation of market players in product innovation and development, and an increase in the approvals of products are likely to fuel the growth of the benign prostatic hyperplasic devices market during the forecast period.
On the contrary, restricted awareness about prostate health among men.
Based on product, the Europe benign prostatic hyperplasic devices market is segmented into resectoscopes, urology lasers, radiofrequency ablation devices, prostatic stents, and implants. The resectoscopes segment held 34.7% market share in 2022, amassing US$ 224.73 million. It is projected to garner US$ 341.22 million by 2028 to expand at 7.2% CAGR during 2022–2028.
Based on procedure type, the Europe benign prostatic hyperplasic devices market is segmented into transurethral microwave therapy, transurethral resection of the prostate, transurethral needle ablation of the prostate, laser surgery, urolift surgery, and others. The transurethral resection of the prostate segment held 28.6% market share in 2022, amassing US$ 185.43 million. It is projected to garner US$ 294.13 million by 2028 to expand at 8.0% CAGR during 2022–2028.
Based on end user, the Europe benign prostatic hyperplasic devices market is segmented into hospitals, clinics, ambulatory surgical centers, and others. The hospitals segment held 41.6% market share in 2022, amassing US$ 269.89 million. It is projected to garner US$ 409.90 million by 2028 to expand at 7.2% CAGR during 2022–2028
Based on country, the Europe benign prostatic hyperplasic devices market has been segmented into the U.K., Germany, France, Italy, Spain, and Rest of Europe. Our regional analysis states that Germany captured 26.6% market share in 2022. It was assessed at US$ 172.17 million in 2022 and is likely to hit US$ 266.95 million by 2028, exhibiting a CAGR of 7.6% during the forecast period.
Key players dominating the Europe benign prostatic hyperplasic devices market are KARL STORZ SE & Co. KG; Olympus Corporation; Boston Scientific Corporation; Teleflex Incorporated; and Richard Wolf GmbH among others.
In June 2019, ProArc Medical received a $2.2 million grant from the prestigious Horizon 2020 program as a part of the European Innovation Council pilot. The two-year grant supports further scientific studies and commercialization of ProArc’s ClearRing BPH implant. In September 2021, Teleflex Incorporated’s two new UroLift System products, the UroLift Advanced Tissue Control (ATC) System and the UroLift 2 System, will be launched at the American Urological Association (AUA) 2021 Annual Meeting.
Related Reports
- $3,000.00 – $5,000.00
